Stephen H. Norris - Concepedia

Author

Stephen H. Norris

Boehringer Ingelheim (United States)ORCID

Also Known As

S. H. Norris, S. Norris, S.H. Norris, STEPHEN H. NORRIS, Stephen H Norris, Stephen H. Norris, Stephen Norris

Publications

Citations

H-Index

Concepts

All Affiliations

Boehringer Ingelheim (United States)Boehringer Ingelheim (Germany)SOUSEIKAI Global Clinical Research Center Boehringer Ingelheim (Belgium)Boehringer Ingelheim (Japan)

About

Stephen H. Norris is an author at Boehringer Ingelheim (United States) specializing in medicine, immunology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	763
2	Biochemistry	2	2	90
3	Language Studies	1	1	35
4	Natural Sciences	1	1	41
5	Allergy	1	1	49

Stephen H. Norris

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Pulmonary Aspergillosis in the Acquired Immunodeficiency Syndrome David W. Denning, Stephen Follansbee, Michael J. Scolaro, New England Journal of Medicine	1991	503
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial Stephan Glund, Joachim Stangier, Michael Schmohl, The Lancet ThrombosisVenous ThrombosisCardiovascular DiseaseAnticoagulant EffectHealthy Male Volunteers	2015	317
Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1 Arthur F. Kavanaugh, Laurie S. Davis, Lisa Nichols, Arthritis & Rheumatism	1994	264
A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran Viktoria Moschetti, Stephen H. Norris, Joachim Stangier, Thrombosis and Haemostasis Drug SafetyTranslational MedicineMonoclonal Antibody FragmentIdarucizumab DoseHealthy Volunteers	2015	244
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study Stephan Glund, Joachim Stangier, Joanne van Ryn, Clinical Pharmacokinetics	2016	85
Safety, Pharmacokinetics and Biological Activity of Enlimomab (Anti-ICAM-1 Antibody): An Open-Label, Dose Escalation Study in Patients Hospitalized for Acute Stroke Dietmar Schneider, Jörg Berrouschot, Tobias Brandt, European Neurology	1998	75
Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects Stephan Glund, Joachim Stangier, Michael Schmohl, Blood	2014	70
Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers Thomas R. MacGregor, John P. Sabo, Stephen H. Norris, HIV Clinical Trials	2004	64
Isotype choice for chimeric antibodies affects binding properties. Maurice M. Morelock, Robert Rothlein, Susan Bright, Journal of Biological Chemistry Immunocytochemical TechniqueMurine Antibody Birr1Isotype ChoiceImmunologyGlycobiology	1994	51
ANTIBODY ENZYME CONJUGATES THE PREPARATION OF INTERMOLECULAR CONJUGATES OF HORSERADISH PEROXIDASE AND ANTIBODY AND THEIR USE IN IMMUNOHISTOLOGY OF RENAL CORTEX David H. Clyne, Stephen H. Norris, Rosario R. Modesto, Journal of Histochemistry & Cytochemistry Immunocytochemical TechniqueHorseradish PeroxidaseAllergyBiochemistryBioanalysis	1973	49

Page 1